The FDA has granted accelerated approval to Zynyz (retifanlimab) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Military pilots and the ground crews who fuel and maintain their aircraft have higher rates of certain cancers, a new study shows.
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Oral nicotinamide does not reduce the risk of keratinocyte cancers in organ transplant recipients, a study suggests.
Authors present a concise overview of the diagnosis, risk factors, and treatment of basal cell carcinoma.
Personalized ctDNA monitoring can predict outcomes during and after treatment in patients with advanced melanoma, a study suggests.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
The application is supported by data from the phase 3 CheckMate76K trial.
Methotrexate use may be associated with an increased risk of skin cancer, but more research is needed.
The FDA has granted breakthrough therapy designation to mRNA-4157/V940 in combination with pembrolizumab to treat melanoma.
Nivolumab plus relatlimab can produce durable responses in patients with advanced melanoma whose disease progressed on anti-PD-1/PD-L1 regimens.
Phase 3 trials for metastatic breast cancer, lung cancer, and melanoma do not include leptomeningeal disease-specific endpoints.
Survival outcomes of advanced melanoma are worse for AYAs than for older adults, a study suggests.
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
Patient-reported outcomes in oncology trials are similar whether the trials have open-label or blinded designs, new research suggests.
Centers that perform comprehensive cancer screening in a single appointment may enable earlier cancer diagnosis.
Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.